GI Bleeding and Thromboembolic Event Risks of DOACs vs. Warfarin After Elective Endoscopy

Rates of gastrointestinal bleeding and thromboembolic events 30 days after an endoscopic procedure were similar with each drug.

Anticoagulants, including direct-acting oral anticoagulants (DOACs) and warfarin, are increasingly used in the management of patients with cardiovascular disease. Although the overall risks for associated bleeding and intracranial hemorrhage events are lower with DOACs compared with warfarin, DOACs carry an increased risk for gastrointestinal (GI) bleeding. However, the comparative risks of DOACs and warfarin for GI bleeding and thromboembolic events (TEs) after endoscopic procedures are unknown.

To investigate these risks, researchers conducted a retrospective cohort study in patients on DOACs or warfarin who underwent an outpatient endoscopic procedure within an integrated healthcare system in California. Of 6765 procedures examined, 1587 …

Reviewing Author

John R. Saltzman, MD

Disclosures

Consultant/Advisory BoardIterative Scopes

Editorial BoardsGastrointestinal Endoscopy; UpToDate

Leadership Positions in Professional SocietiesAmerican College of Gastroenterology (Trustee)

OtherVice President of Medical Affairs, 1Globe Health Institute